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journa l homepage : www.e lsev ier . com/ loca te / rmedLETTER TO THE EDITORCough and transdermal long-acting b2 agonist in JapanDear Editor,
Tamura and Ohta reported higher treatment compliance
with the tulobuterol patch, a transdermal long-acting b2
agonist, than with inhaled drugs in patients with asthma
or COPD due to administration once daily.1 However, we
are quite concerned with the over adherence of the tulobu-
terol patch in Japan. The tulobuterol patch is now widely
regarded as an anti-tussive agent not only for individuals
with asthma, but also for those suffering from acute bron-
chitis or the common cold.
Parents of young children refer to these patches as
‘‘anti-tussive tape’’. Tulobuterol patches are frequently
prescribed by pediatricians due to strong demands from
parents of children suffering from cough. For young
children, the transdermal drug has much better adherence
and compliance than oral drugs which usually taste bitter or
bad.
The anti-tussive effect of tulobuterol is primarily based
on its bronchodilatory properties. Among the sensory
nerves innervated in the lung, there is a general consensus
that rapidly adapting receptors (PAR) and bronchopulmo-
nary unmyelinated C-fibers are directly responsible for the
initiation of cough.2 The inflammatory mediators lowered
the threshold of the sensitivities of these sensory nerves.2
Different from receptors to chemical stimuli such as C-
fibers, PAR is a mechanoreceptor which is activated by
irritant stimuli and bronchospasm. Therefore, tulobuterol
could restore the cough reflex threshold of PAR but not of
C-fibers.
b2 agonist, a sympathetic nerve stimulator, has a variety
of side effects including burden to the heart. Due to the
limited site of action and relatively larger side effects, b2
agonist had not been used as a general anti-tussive drug
prior to the development of transdermal formulations.
Because the transdermal formulation of long-acting b2 ago-
nist is approved only in Japan and Korea, we might be the
only people in the world to use long-acting b2 agonist as
a non-specific anti-tussive therapy. Evidence for effective-
ness and safety is poor.0954-6111/$ - see front matter ª 2008 Elsevier Ltd. All rights reserved
doi:10.1016/j.rmed.2008.03.005Excessive coughing is often linked to underlying pathol-
ogy such as infection, asthma, gastro-esophageal reflux,
and in some cases can be alleviated with disease-specific
therapy.3 However, the cause of cough may not always be
definable and, in some patients, treating the underlying
disease may not reduce coughing. In some cases, a non-
specific anti-tussive therapy is needed for cough suppres-
sion. Currently available anti-tussive agents offer little
benefit over placebo for cough relief.4
The rapid spread of the tulobuterol patch as a non-
specific anti-tussive therapy suggests an advantage.
However, due to the efficacy and safety concerns, we
should reconsider the use of the transdermal long-acting b2
agonist as a non-specific anti-tussive agent.References
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